Atrial fibrillation: Difference between revisions
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
==[[Atrial fibrillation overview|Overview]]== | ==[[Atrial fibrillation overview|Overview]]== | ||
==Atrial fibrillation historical perspective== | ==[[Atrial fibrillation historical perspective]]== | ||
==[[Atrial fibrillation classification|Classification]]== | ==[[Atrial fibrillation classification|Classification]]== |
Revision as of 16:04, 22 July 2021
Resident Survival Guide |
Sinus rhythm |
Atrial fibrillation |
Atrial Fibrillation Microchapters | |
Special Groups | |
---|---|
Diagnosis | |
Treatment | |
Cardioversion | |
Anticoagulation | |
Surgery | |
Case Studies | |
Atrial fibrillation On the Web | |
For patient information, click here. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: AF; afib; lone fibrillator
Overview
Atrial fibrillation historical perspective
Classification
Pathophysiology
Causes
Differentiating Atrial Fibrillation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Special Groups
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy | Patients Presenting with ACS and/or PCI or Valve Intervention
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Afib with LBBB EKG Examples | Chest X Ray | Echocardiography | Holter Monitoring and Exercise Stress Testing | Cardiac MRI
Treatment
Rate and Rhythm Control
Rate Control | Maintenance of Sinus Rhythm
Cardioversion
Overview | Electrical Cardioversion | Pharmacological Cardioversion
Anticoagulation
Overview | Warfarin | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants | Dabigatran
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Ablation
Catheter Ablation | AV Nodal Ablation | Surgical Ablation